Sheryl A Kingsberg Selected Research

Psychological Sexual Dysfunctions (Sexual Arousal Disorder)

1/2022	Safety Profile of Bremelanotide Across the Clinical Development Program.
12/2021	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
11/2021	Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
1/2021	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
1/2021	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
12/2019	Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects.
11/2019	Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
11/2019	Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
11/2019	Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study.
10/2019	Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sheryl A Kingsberg Research Topics

Disease

15	Psychological Sexual Dysfunctions (Sexual Arousal Disorder) 01/2022 - 05/2005
8	Atrophy 08/2017 - 06/2013
6	Nausea 01/2022 - 06/2014
5	Headache (Headaches) 01/2022 - 06/2014
4	Dyspareunia 08/2017 - 04/2014
3	Flushing 01/2022 - 11/2019
3	Hypotension (Low Blood Pressure) 12/2019 - 01/2019
3	Syncope (Fainting) 12/2019 - 01/2019
3	Breast Neoplasms (Breast Cancer) 01/2019 - 09/2008
3	Dizziness (Lightheadedness) 01/2019 - 06/2014
3	Sleepiness 01/2019 - 06/2014
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 09/2008
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2019 - 01/2017
2	Neoplasms (Cancer) 01/2018 - 07/2013
1	Hyperpigmentation 01/2022
1	Injection Site Reaction 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Orthostatic Hypotension (Postural Hypotension) 11/2019
1	Weight Loss (Weight Reduction) 10/2019
1	Overweight 10/2019
1	Pain (Aches) 01/2019
1	Fatigue 01/2019
1	Triple Negative Breast Neoplasms 01/2018
1	Purpura 04/2014
1	Atrophic Vaginitis 06/2013

Drug/Important Bio-Agent (IBA)

6	Testosterone (Sustanon)FDA Link 01/2022 - 05/2005
6	flibanserin (BIMT 17)IBA 12/2019 - 06/2014
5	bremelanotideIBA 01/2022 - 11/2019
5	Estrogens (Estrogen)FDA Link 01/2019 - 05/2005
3	TX-004HRIBA 08/2017 - 12/2016
2	Ethanol (Ethyl Alcohol)IBA 12/2019 - 11/2019
2	Serotonin Receptor Agonists (Serotonin Receptor Agonist)IBA 10/2019 - 06/2014
2	Estrogen ReceptorsIBA 01/2018 - 04/2014
2	Hormones (Hormone)IBA 01/2018 - 07/2009
2	trichostatin A (A 300)IBA 07/2009 - 05/2005
1	Melanocortin Receptors (Melanocortin Receptor)IBA 01/2022
1	Pharmaceutical PreparationsIBA 11/2019
1	Tryptamines (Triptans)IBA 01/2019
1	Antidepressive Agents (Antidepressants)IBA 01/2019
1	Capsules (Microcapsules)IBA 08/2017
1	Serotonin ReceptorsIBA 06/2014
1	OspemifeneIBA 04/2014

Therapy/Procedure

10	Therapeutics 01/2021 - 05/2005
1	Aftercare (After-Treatment) 12/2021
1	Activities of Daily Living (ADL) 01/2019
1	Hysterectomy 05/2005
1	Ovariectomy (Oophorectomy) 05/2005